However, the new study finds a higher risk of kidney replacement therapy with continuation of angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy.
Researchers’ goal was to determine empagliflozin’s impact on the central hemodynamic parameters of patients with heart failure with reduced ejection fraction.
Greater eGFR variability may identify individuals at higher mortality risk whether or not they have chronic kidney disease, according to investigators.
